Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. GenSight Biologics S.A.
  6. Company
    SIGHT   FR0013183985

GENSIGHT BIOLOGICS S.A.

(SIGHT)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Business Summary
GenSight Biologics S.A. specializes in the research and development of gene therapies for the treatment of mitochondrial diseases and eye neurodegeneratives.

At the end of 2020, the company had a portfolio of 2 products, including 1 in phase III clinical development (GS010 for the treatment of Leber's hereditary optic neuropathy) and 1 in phase I/II clinical development (GS030 for the treatment of retinitis pigmentosa).

Number of employees : 25 people.
Sales per Business
20192020Delta
EUR (in Million)%EUR (in Million)%
Novel Therapies for Mitochondrial and Neurodegenerative Disease0.700100%4.39100% +527.71%
Sales per region
20192020Delta
EUR (in Million)%EUR (in Million)%
France0.700100%4.39100% +527.71%
Managers
NameAgeSinceTitle
Bernard Jacques Alex Gilly, Dr.632016Chief Executive Officer & Director
Thomas Gidoin372015Chief Financial Officer
Magali Taiel, Dr.-2019Chief Medical Officer
Marion Ghibaudo, Dr.-2021Chief Technical Officer
Laurence Rodriguez-2021Director-Operations
Michael S. Wyzga652016Chairman
Peter Goodfellow, Dr.682014Independent Director
Simone Seiter, Dr.-2017Independent Director
Maritza C. McIntyre, Dr.-2019Independent Director
Elsy Boglioli Hofman38-Independent Director
Members of the board
NameAgeSinceTitle
Michael S. Wyzga652016Chairman
Bernard Jacques Alex Gilly, Dr.632016Chief Executive Officer & Director
José-Alain Sahel, Dr.65-Director
Peter Goodfellow, Dr.682014Independent Director
Simone Seiter, Dr.-2017Independent Director
Maritza C. McIntyre, Dr.-2019Independent Director
Cédric Moreau-2019Director
Elsy Boglioli Hofman38-Independent Director
Françoise De Craecker-2021Independent Director
Equities
Vote QuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 40,875,965 40,100,482 98.1% 0 0.0% 98.1%
Shareholders
NameEquities%
Sofinnova Partners SAS 5,610,044 12.2%
Amiral Gestion SA 2,529,000 5.50%
Bpifrance Participations SA /PRIVATE EQUITY/ 1,923,255 4.18%
Versant Venture Management LLC 1,576,428 3.43%
Abingworth LLP 1,402,588 3.05%
Novartis AG 1,390,487 3.02%
Vitavest S.à.r.l. 1,339,706 2.91%
BPIFrance Investissement SAS 1,213,761 2.64%
Argenta Banque d'Epargne SA 454,379 0.99%
Arctic Fund Management AS (Sweden) 372,231 0.81%
Markets and indexes
- PEA / SRD eligible : YES / YES
-
- Compartiment B
- CAC Small / CAC All Shares, CAC All-Tradable, CAC Mid Small, CAC PME, EnterNext© PEA-PME 150, Next Biotech, PEA, PEA-PME
Stock Exchange Codes
- Bloomberg Code :  SIGHT:FR
- Reuters Code :  SIGHT.PA
- Datastream Code :  
Company contact information
GenSight Biologics S.A.
74 Rue du Faubourg Saint-Antoine
FR-75012 Paris


Phone : +33 (0)1 76 21 72 20
Fax :
web site : http://www.gensight-biologics.com
Brand Portfolio
In partnership withAllbrands.markets
More brands of GenSight Biologics S.A.
Sector Bio Therapeutic Drugs